September 2021

Research Reveals How PARP Inhibitors Work
A recent study published in Genes & Development conducted by researchers from Massachusetts General Hospital suggests that poly[ADP-ribose] polymerase (PARP) inhibitors are effective against BRCA1 and BRCA2 mutations. Read more.


One-Half of Low-Risk PC Patients Transition From Active Surveillance to Active Treatment
According to a study in the Journal of Urology, within a few years after diagnosis, an estimated 50% of men who were initially managed with active surveillance for "low-risk" prostate cancer (PC) shift to definitive treatment, such as surgery or radiation therapy. Read more.

PARP Inhibitor Maintenance Therapy Expanding in Recurrent Ovarian Cancer
The use of maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer has been confirmed in several clinical trials, but a recent study in Gynecologic Oncology explored the real-world treatment patterns for this type of cancer. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App